Gregory A. Abel, MD, MPH

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 1106
Boston, MA
USA 02115
888 Bcor Mutations Cooperate with Tet2 Deficiency to Promote RAS Transformation of Mouse Hematopoietic Progenitors
972 Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study
973 Impact of Timing and Location of Goals of Care Discussions for Patients with Blood Cancers
1819 Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities
2291 Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)
4370 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study
4378 Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria
4750 Outcomes for Older Patients with Acute Myeloid Leukemia after Admission to the Intensive Care Unit (ICU)